Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2021-10-01 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
EPO Patent Granted
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly mentions being provided by 'RNS, the news service of the London Stock Exchange.' It announces a specific corporate event (EPO Patent Granted) and concludes by stating that the information is considered inside information and is now in the public domain upon publication via the Regulatory Information Service (RNS). This structure strongly indicates a general regulatory announcement that does not fit the more specific categories like 10-K, ER, or DIV. Since it is a general regulatory announcement distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory news.
2021-10-01 English
Publication of data in glioblastoma cells
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number '1988M' and the header 'Evgen Pharma PLC'. The content discusses the publication of new scientific data regarding the effectiveness of their asset SFX-01 in glioblastoma cells, referencing a pre-print journal (BioRxIV). The document concludes with contact information and a disclaimer stating, 'Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature.' This structure—a brief announcement about new, non-mandated information (like scientific findings or general corporate updates) distributed via the RNS distribution service but explicitly marked as non-regulatory—fits the description of a general regulatory announcement or a miscellaneous filing that doesn't fit a specific financial report category. Since it is not a formal report (like 10-K, IR, ER) but a general update distributed through the regulatory news service infrastructure, the most appropriate fallback category is Regulatory Filings (RNS). The document length (5279 chars) is substantial enough that it is not just a simple 'Report Publication Announcement' (RPA), which usually just announces the availability of another document.
2021-09-20 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results' for N4 Pharma PLC for the six months ended 30 June 2021. It contains detailed financial statements, including the 'Condensed Consolidated Interim Statement of Comprehensive Income' and 'Condensed Consolidated Interim Statement of Financial Position', along with management commentary. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2021
2021-09-20 English
Operations Update
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'RNS, the news service of the London Stock Exchange' and 'Regulatory Information Service ('RIS')'. It provides an 'Operations Update' regarding in vitro and in vivo testing progress for a SARS-COV-2 plasmid using their Nuvec® system. This is a general, timely announcement of operational progress and inside information, not a comprehensive financial report (like 10-K or IR), a specific voting result (DVA), or a management change (MANG). Since it is a regulatory announcement distributed via RIS/RNS that doesn't fit a more specific category like ER, DIV, or CAP, the most appropriate classification is the general regulatory filing category.
2021-09-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 5839K' and concludes with text stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'TR-1: Standard form for notification of major holdings' regarding an acquisition of voting rights by an individual, crossing a threshold (from 8.73% to 9.09%). This specific type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2021-09-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1935 characters) and announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, identified by the 'RNS Number : 5820K'. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, IR, or 10-K. Since it is a regulatory announcement that doesn't fit the specific categories (like DIRS, DIV, or DLST), the most appropriate classification is the general Regulatory Filings fallback category.
2021-09-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.